- Home
- PAVS vs INAB Comparison
PAVS vs INAB Comparison
Compare PAVS & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVS
- INAB
- Stock Information
- Founded
- PAVS 2004
- INAB 2016
- Country
- PAVS United States
- INAB United States
- Employees
- PAVS N/A
- INAB N/A
- Industry
- PAVS Medicinal Chemicals and Botanical Products
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- PAVS Health Care
- INAB Health Care
- Exchange
- PAVS Nasdaq
- INAB Nasdaq
- Market Cap
- PAVS 89.6M
- INAB 14.5M
- IPO Year
- PAVS 2019
- INAB 2021
- Fundamental
- Price
- PAVS $0.84
- INAB $2.09
- Analyst Decision
- PAVS
- INAB Strong Buy
- Analyst Count
- PAVS 0
- INAB 2
- Target Price
- PAVS N/A
- INAB $108.00
- AVG Volume (30 Days)
- PAVS 3.7K
- INAB 385.7K
- Earning Date
- PAVS 07-31-2025
- INAB 08-07-2025
- Dividend Yield
- PAVS N/A
- INAB N/A
- EPS Growth
- PAVS N/A
- INAB N/A
- EPS
- PAVS N/A
- INAB N/A
- Revenue
- PAVS $6,613,273.00
- INAB N/A
- Revenue This Year
- PAVS N/A
- INAB N/A
- Revenue Next Year
- PAVS N/A
- INAB N/A
- P/E Ratio
- PAVS N/A
- INAB N/A
- Revenue Growth
- PAVS 2.50
- INAB N/A
- 52 Week Low
- PAVS $0.32
- INAB $2.06
- 52 Week High
- PAVS $1.50
- INAB $27.60
- Technical
- Relative Strength Index (RSI)
- PAVS 36.13
- INAB 27.49
- Support Level
- PAVS $0.82
- INAB $2.06
- Resistance Level
- PAVS $0.87
- INAB $2.31
- Average True Range (ATR)
- PAVS 0.04
- INAB 0.31
- MACD
- PAVS 0.00
- INAB -0.00
- Stochastic Oscillator
- PAVS 12.14
- INAB 4.74
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.